Sickle Cell Anemia Breakthrough: Targeting HbS, HbF, and Oxygenation with Next-Gen Carriers
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”HbS, HbF and Oxygenation in Sickle Cell Disease: A New Playbook With BHOC
HbS = The Saboteur
A single mutation → sickled cells → blocked vessels → pain and tissue damage. Severity is directly proportional to HbS levels.
HbF = The Natural Defender
Keep HbF above 20–30% and sickling is suppressed at the molecular level. Fewer crises, less cumulative organ damage.
Oxygenation = The Silent Hero
HbS polymerizes only when deoxygenated. Stabilizing oxygenated HbS—as voxelotor attempts—reduces sickling. Sustainable, side-effect-free approaches are still needed.
BHOCs = The Game Changer
Next-generation Blood Hemoglobin-Based Oxygen Carriers (BHOCs) deliver oxygen precisely where it’s needed—intervening before polymerization occurs.
Clinical evidence is still developing, but the concept is scientifically sound. Properly designed trials are key.
About future possibility
- BHOC can serve as a bridge to recovery. We believe it can transform the approach to Sickle Cell Anemia (SCA) treatment by providing supportive, low-volume infusion therapy before HbS levels become critical.
Much like insulin regulates blood sugar and HbA1c levels, BHOC can help support and control HbS polymerization levels, stabilizing oxygen delivery and patient condition.
Call to Action
- Stop just managing crises. Start preventing them. Let’s explore early warning systems integrating:
SaO₂, PaO₂, CaO₂, Hb, HbS polymerization levels — measurable with existing devices. Let’s act before the crisis hits.
Contact us for collaboration or discussion about clinical applications and partnerships.
Stay informed with Hemostasis Today.
-
Nov 25, 2025, 14:18From Ticagrelor to Prasugrel․ ISAR-REACT 5 Findings Redefine Clinical Practice
-
Nov 25, 2025, 12:03Ana Rita Rodrigues on Post-Stroke Oropharyngeal Dysphagia
-
Nov 25, 2025, 11:24Amy Goundry Takes on The Role of Managing Editor for Therapeutic Advances in Cardiovascular Disease
-
Nov 25, 2025, 11:01Jack Shuang Hou: Asundexian Hits Phase 3 Stroke Endpoint Without Increasing Bleeding Risk
-
Nov 25, 2025, 10:37Moin Makda: HemeNext Felt Like a Full Circle Moment
-
Nov 25, 2025, 10:14Lucas Di Meglio and Team Show That Targeting Extracellular DNA Mayy Reduce Microvascular Thrombosis
-
Nov 25, 2025, 09:54Hema Tallman on BioLife Plasma Services Leaders Spreading Holiday Cheer through Volunteerism
-
Nov 25, 2025, 09:36Stefan Hof on The Role of Pyrrolidine Dithiocarbamate in Hemorrhagic Shoke
-
Nov 25, 2025, 09:29Ashkan Shoamanesh: Should Intracranial Hemorrhage Survivors with AFib Receive Anticoagulation?